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Abstract
Background: Sorafenib monotherapy in patients with metastatic melanoma was explored in this multi-institutional phase II
study. In correlative studies the impact of sorafenib on cyclin D1 and Ki67 was assessed.
Methodology/Principal Findings: Thirty-six patients treatment-naı ¨ve advanced melanoma patients received sorafenib
400 mg p.o. twice daily continuously. Tumor BRAF
V600E mutational status was determined by routine DNA sequencing and
mutation-specific PCR (MSPCR). Immunohistochemistry (IHC) staining for cyclin D1 and Ki67 was performed on available
pre- and post treatment tumor samples. The main toxicities included diarrhea, alopecia, rash, mucositis, nausea, hand-foot
syndrome, and intestinal perforation. One patient had a RECIST partial response (PR) lasting 175 days. Three patients
experienced stable disease (SD) with a mean duration of 37 weeks. Routine BRAF
V600E sequencing yielded 27 wild-type (wt)
and 6 mutant tumors, whereas MSPCR identified 12 wt and 18 mutant tumors. No correlation was seen between BRAF
V600E
mutational status and clinical activity. No significant changes in expression of cyclin D1 or Ki67 with sorafenib treatment
were demonstrable in the 15 patients with pre-and post-treatment tumor samples.
Conclusions/Significance: Sorafenib monotherapy has limited activity in advanced melanoma patients. BRAF
V600E
mutational status of the tumor was not associated with clinical activity and no significant effect of sorafenib on cyclin
D1 or Ki67 was seen, suggesting that sorafenib is not an effective BRAF inhibitor or that additional signaling pathways are
equally important in the patients who benefit from sorafenib.
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Introduction
Metastatic melanoma is an aggressive skin cancer that is largely
resistant to most systemic treatments. Response rates (RR) with
dacarbazine, which remains the reference standard agent for
advanced disease, have been in the 8–12% range in recent large,
randomized trials [1,2,3]. Consequently, alternative treatments are
being intensively investigated. Promising alternative approaches
include strategies to target specific oncogenes and oncogenic
pathways.
Activating mutations of the BRAF oncogene have been found in
50–60% of primary melanoma, metastatic melanoma tissues, and
melanoma cell lines by us and other groups [4,5,6]. BRAF
V600E,
which accounts for more than 90% of BRAF mutations, leads to
constitutive activation of downstream signaling via the MAPK
cascade, a pathway that is critical in cell cycle regulation and
proliferation [7]. Inhibition of the activated MAPK pathway
through BRAF silencing with RNA interference results in
apoptosis of melanoma cell lines carrying the BRAF
V600E
mutation [8,9,10] and regression of BRAF
V600E melanoma
xenografts [11], suggesting that BRAF is an attractive drug target.
Sorafenib is an orally active multikinase agent that inhibits
BRAF and CRAF as well as a number of other cellular targets
such as vascular endothelial growth factor receptors (VEGFR,
particularly VEGFR-2), platelet-derived growth factor receptor
(PDGFR), FMS-like tyrosine kinase 3 (Flt-3); c-Kit protein (c-Kit);
and RET receptor tyrosine kinases [12,13]. It has recently gained
FDA approval for use in advanced renal cell carcinoma [14] and
hepatocellular carcinoma [15]. In preclinical studies, sorafenib was
shown to block the activation of the MAPK downstream molecules
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xenograft models [9,16]. No PR’s were seen in 37 advanced
melanoma patients who were treated with sorafenib monotherapy
as part of a randomized discontinuation trial [17]. In a
randomized phase II trial, the combination of dacarbazine and
sorafenib demonstrated superior objective responses and progres-
sion-free survival (but no improved overall survival) [18], whereas
a phase III trial of the Eastern Oncology Group (ECOG), E2603,
randomizing advanced melanoma patients to paclitaxel and
carboplatin with or without sorafenib recently failed its primary
endpoint of overall survival in a planned interim analysis [19].
The primary rationale of the current study was to explore the
safety and efficacy of sorafenib monotherapy in patients with
metastatic melanoma. Correlative studies were conducted to
investigate the effect of this treatment on cyclin D1 or Ki67. We
also aimed to assess an association between BRAF
V600E muta-
tional status in metastatic melanoma patients and response to
sorafenib therapy.
Methods
The protocol for this trial and supporting CONSORT checklist
are available as supporting information; see Checklist S1 and
Protocol S1.
Ethics
This study was conducted according to the principles expressed
in the Declaration of Helsinki. The protocol (NCI study number
NCI-6617, Clinical Trials.gov identifier NCT00119249) received
prior approval by the institutional review board at New York
University Langone Medical Center. The protocol was reviewed
by the local institutional review board at each participating
institution, and all patients provided written informed consent.
Participants
Patients were eligible if they were at least 18 years of age, had
histologically or cytologically confirmed, unresectable, stage III or
stage IV melanoma and a life expectancy $3 months. All patients
had measurable disease according to the international criteria
proposed by the Response Evaluation Criteria in Solid Tumors
(RECIST) committee [20]. Other eligibility criteria were adequate
performance status (Eastern Cooperative Oncology Group 0–2 or
Karnofsky $60%), adequate renal, hepatic, and bone marrow
function (serum creatinine #1.5 times the upper limit of normal
[ULN]), total bilirubin #2 times ULN, AST (SGOT) and ALT
(SGPT) #2.5 times ULN, absolute neutrophil count $1.5610
9/l,
platelet count $100610
9/l). Patients with brain metastases were
eligible if they were steroid-independent with radiographically
stable lesions for at least 6 weeks after whole brain radiation and
no mass effect present radiographically at the time of study entry.
Patients who had received previous chemotherapy for metastatic
disease were not enrolled. Pregnant or nursing patients and
patients who were receiving any other investigational agents were
excluded from the study. Exclusion criteria also comprised a
history of serious allergic reactions to eggs (sorafenib is formulated
using egg phospholipids), disorders that would interfere with oral
intake of the study drug, HIV positive patients receiving
combination anti-retroviral therapy (due to possible pharmacoki-
netic interactions with the study drug), patients with an active
infection or with other indications of poor medical risk, and
patients with any evidence of bleeding diatheses. The study was
conducted by the New York Cancer Consortium (www.new
yorkcancerconsortium.org). The participating institutions were
New York University Langone Medical Center, New York, NY
and Sydney Cancer Center, Sydney, Australia.
Interventions
All patients received sorafenib orally at a dose of 400 mg twice a
day on days 1 to 28 (one treatment cycle). Treatment cycles were
repeated every 28 days until unacceptable toxicity, disease
progression, or death. Growth factor support was used as per
American Society of Clinical Oncology guidelines. Sorafenib was
dose-reduced by 200 mg per day if patients had clinically
significant hematologic or other adverse events as measured by
revised NCI Common Toxicity Criteria (CTC) version 3.0 and the
events were felt to be attributable to sorafenib. More than 2 dose
reductions or dose re-escalation was not allowed; treatment was
discontinued if any grade 3 or 4 toxicity did not resolve within 3
weeks.
Objectives
The objectives of this single arm, phase II trial were to assess the
efficacy and toxicity of sorafenib in metastatic melanoma patients.
Furthermore, the impact of sorafenib on cyclin D1 and Ki67 as
well as BRAF
V600E mutational status was to be assessed. The
hypotheses were that sorafenib has efficacy in this patient
population that cyclin D1 and Ki67 are impacted in melanoma
tissue, and that clinical responses are associated with the presence
of a BRAF
V600E mutation.
Outcomes
The primary endpoint was RR, while secondary endpoints were
time to progression (TTP) and toxicity. Prior to each treatment
cycle, patients were evaluated by medical history, physical
examination, assessment of Eastern Cooperative Oncology Group
performance status, complete blood counts, and serum chemis-
tries. Tumor response was assessed after every 2 cycles (8 weeks) of
treatment using appropriate imaging (computer-assisted tomogra-
phy (CT), positron-emission-tomography combined with CT, or
magnetic resonance imaging) and outcomes were evaluated
according to RECIST criteria. Stable disease had to last at least
6 months in order to be qualified as such [21]. Duration of a
partial response (PR) was defined as the time that the response was
first documented until progression, whereas duration of stable
disease (SD) was defined as the time from treatment initiation until
progression. Patients were treated until disease progression or
development of unacceptable toxicities.
Attempts were made to obtain punch biopsies of soft tissue
melanoma lesions from all patients on day 1 (pre-treatment) and
day 28 of the first cycle. Immunohistochemistry staining for cyclin
D1 and Ki67 was performed on paraffin embedded tissue from
day 1 and day 28 biopsy samples. BRAF
V600E mutation analysis
(as described below) and H&E staining for confirmation of the
melanoma diagnosis was performed on paraffin embedded tissue
from day 1 punch biopsy specimens in all patients.
Correlative Studies
Patient tissue was analyzed for the presence of BRAF
V600E
mutation with both conventional DNA sequencing and the more
sensitive mutation-specific PCR (MSPCR) as described previously
[6,22]. Briefly, DNA was extracted from paraffin embedded tumor
tissue using QIAamp Mini DNA kit (QIAGEN). The melanoma
cell line SK-MEL29 [23] was used as BRAF
V600E positive control,
human placental DNA (Sigma-Aldrich, St. Louis, MO) as negative
control. The forward, mutant-specific primer has 2 bases at the 39
end that do not anneal to the wild-type sequence, whereas the
Phase II Trial of Sorafenib in Metastatic Melanoma
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resulting in specific amplification of the V600E mutant allele.
The reverse primer was labeled with HEX fluorochrome to allow
detection using an ABI 310 Genetic Analyzer (Applied Biosys-
tems). For conventional sequencing, the entire BRAF exon 15 was
amplified using primers as previously described [4]. Exon 11 was
not amplified.
Immunohistochemistry (IHC) was performed on formalin fixed,
paraffin embedded 3 micron tissue sections using mouse anti-
cyclin D1 (clone P2D11F11) and mouse anti-Ki-67 (clone K-2)
(Ventana Medical Systems Tucson, AZ USA). In brief, sections
were deparaffinized in xylene (3 changes), rehydrated through
graded alcohols (3 changes 100% ethanol, 3 changes 95% ethanol)
and rinsed in distilled water. Heat induced epitope retrieval was
performed in 10mM citrate buffer pH 6.0 in a 1200-Watt
microwave oven at 90% power. All antibodies were retrieved for
20 minutes and sections were allowed to cool for 30 minutes
followed by rinsing in distilled water. Antibody incubations and
detection were carried out at 37uC on a NEXes instrument
(Ventana Medical Systems Tucson, Arizona) using Ventana’s
reagent buffer and detection kits unless otherwise noted.
Endogenous peroxidase activity was blocked with hydrogen
peroxide. Cyclin D1 and Ki67 were pre-diluted and incubated
for 30 minutes. Primary antibodies were detected with Ventana’s
biotinylated goat anti-mouse or goat anti-rabbit secondary
antibody, respectively. After secondary antibody application,
streptavidin-horseradish-peroxidase conjugate was applied. The
complex was visualized with 3,3 diaminobenzidene and enhanced
with copper sulfate. Slides were washed in distilled water,
counterstained with hematoxylin, dehydrated and mounted with
permanent media. Appropriate positive and negative controls
were included with the study sections.
For assessment of IHC staining, five representative tumor
sections (pre-treatment day 1 and post treatment day 28) per tissue
specimen were selected by a board-certified pathologist (using
H&E and IHC-stained samples). The individual cells positive for
cyclin D1 and Ki67, and total number of tumor cells were counted
manually at 406magnification using photographs taken from the
individual tumor sections selected by the pathologist. As part of a
variability assessment, one investigator counted all samples and a
second investigator re-counted one of the 5 (randomly chosen)
replicate tumor sections per specimen. Inter-observer variability
for these confirmatory counts was measured as the difference
between two readings in percent of the mean. The ratios of the
marker positive cells/total tumor cells were calculated from
averages of the five different tumor sections.
Sample Size and Statistical Design
In each subgroup defined by BRAF
V600E status, a Simon two-
stage minimax design was initially proposed to test the null
hypothesis that response rate at the end of the second cycle (56
days) was less than or equal to 5% versus the alternative hypothesis
that the response rate was greater than or equal to 20%. If the
drug was not effective, there was a 3.3% probability of concluding
that it was (type I alpha error). If the drug was effective, there was
a 14.2% probability of concluding that it was not (type II beta
error). After testing the drug on 13 patients per BRAF subgroup in
the first stage, the plan was to terminate the BRAF stratum
(subgroup) if 0 patients per subgroup responded. If the trial
proceeded to the 2
nd stage (for each subgroup), then 37 patients
per BRAF subgroup were to be evaluated for response. If the total
number responding was less than or equal to 4 per subgroup, the
drug was to be rejected for the relevant subgroup. The overall
response rate along with subgroup-specific response rates were to
be estimated at the end of the trial along with 95% confidence
intervals. However, due to accrual limitations, the two-stage design
was applied to the single cohort of 36 patients accrued (i.e.,
comparing 5% versus 20% response rates using the same alpha
and beta errors as indicated above).
Secondary endpoints of progression-free survival (i.e., time to
progression) and toxicity were analyzed for the cohort. Progres-
sion-free survival was calculated using the Kaplan-Meier method
and a 95% confidence interval (95% CI) was estimated for the
median progression-free survival time. Patients with available pre-
treatment and post-treatment correlative markers (cyclin D1 and
Table 1. Patient demographics and disease characteristics.
Parameter No. %
Sex
Male 20 56
Female 16 44
Age, years
Median 64
Range 22–91
Race
Caucasian 35 97
Asian 1 3
Primary site
cutaneous 32 89
mucosal 3 8
ocular 1 3
Stage III
IIIc 2 6
Stage IV
M1a 11 31
M1b 6 17
M1c 17 47
Metastatic site No
17 1 9
21 5 4 2
3 or more 14 39
Site of metastasis
Lung 18 50
Liver 8 22
Bone 6 17
Skin 3 8
Soft tissue 20 56
Lymph nodes (distant) 24 67
Other 8 17
LDH
within normal limits 19 53
elevated 17 47
ECOG Performance Status
02 8 7 8
17 1 9
21 3
doi:10.1371/journal.pone.0015588.t001
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analyses were performed in SAS version 9.2 (SAS Institute, Inc.,
Cary, NC) and Stata version 10.0 (Stata Corporation, College
Station, TX).
Results
Recruitment
Between August 2005 and September 2007, 36 patients were
enrolled at 2 centers in the United States and Autralia. Patients
were followed until disease progression or discontinuation of
treatment due to unacceptable side effects, intercurrent illness, or
patient withdrawal.
Baseline Data
The baseline clinical characteristics for the study population are
summarized in table 1. Median age was 64 years (range, 22 to 91
years); all patients but one had an ECOG performance status of 0–
1. Patients with cutaneous melanoma (31), mucosal melanoma (3),
ocular melanoma (1), and melanoma of unknown primary (1) were
enrolled. Seventeen patients had LDH values 1.16 normal or
higher. Staging was performed according to the American Joint
Committee on Cancer guidelines. Thirty four patients had stage
IV disease and 2 patients had unresectable stage IIIC disease.
Numbers analyzed
All of the 36 patients who were enrolled were analyzed for
toxicity and clinical response (intention to treat). One out of the 36
patients developed rapidly progressive disease prior to initiation of
therapy and never received treatment with sorafenib.
Outcomes and estimation
The median duration of treatment was 63 days. Complete
responses (CR) were not seen in any of the 36 patients; one patient
had a PR that lasted 175 days. Three patients had SD that lasted
between 239 and 288 days (mean 233 days). The response rate (the
primary endpoint of the study) was 1/36=2.8% (95%
CI=0.07%, 14.5%). The disease control rate (CR+PR+SD) was
4/36=11.1% (95% CI=3.1%, 26.1%). Median TTP for
assessable patients was 63 days (95% CI=53 days, 72 days)
(Fig. 1). All patients with either PR or SD who were assessable for
response received treatment until the time of documented disease
progression. Five patients could not be assessed for response:
Three patients withdrew consent prior (2) or shortly after (1)
initiation of treatment, one patient had rapid disease progression
within 2 days of study enrollment, and one patient had a severe
adverse event related to sorafenib prior to the first scheduled
response assessment.
Correlative studies
BRAF mutational analysis was performed using both conven-
tional DNA sequencing and MSPCR. Six out of 33 patients (18%)
for whom BRAF analysis was available tested positive for the
BRAF
V600E mutation by sequencing, whereas 18/30 (60%)
patients were found to carry the mutation as measured by
MSPCR. The cutaneous melanoma patient who experienced a PR
had a BRAF
V600E mutation as tested by both methods (Table 3).
The low disease control rate precludes conclusions about a
correlation between mutational status and response to sorafenib
therapy. All 3 patients with SD were BRAF wild-type by both
methods (Table 3). Individual patients with information on tumor
characteristics, BRAF
V600E status, stage and extension of disease,
and tumor response are listed in table 4.
Immunohistochemistry staining for cyclin D1 and Ki67 was
performed on a subset of patients on day 1 (pre-treatment) and day
28 of the first treatment cycle. We counted 384862264 (mean 6
standard deviation) tumor cells per patient sample (7636463 on
average per replicate). Inter-observer variability was ,6% on
average for the random replicate sample that was counted by a
second investigator. Pre- and post-treatment samples were
Figure 1. Kaplan-Meier analysis of progression-free survival.
doi:10.1371/journal.pone.0015588.g001
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specimens, no tumor was seen. Expression of cyclin D1 and Ki67
was not significantly changed with sorafenib treatment in patients
from which paired pre- and post-treatment samples were available;
the median % change was 214 for cyclin D1 (p=0.18) and 213
for Ki67 (p=0.06) (Fig. 2).
Adverse Events
Sorafenib was well tolerated and most adverse events were
grade 1 or 2, reversible, clinically easily manageable, and did not
require dose reductions (Table 2). The most common adverse
events (possibly, probably, or definitely related) were limited to the
skin and gastrointestinal systems as listed in table 2. Two patients
discontinued sorafenib because of treatment-related adverse events
(hand-foot syndrome and rash). One patient experienced grade II
hypertension and one patient with metastatic disease to the small
bowel experienced grade III intestinal perforation. There were no
reported grade IV adverse events.
Discussion
The primary objective of this trial was the evaluation of efficacy
and tolerability of sorafenib monotherapy in patients with
advanced melanoma. The disease control rate (CR+PR+SD) of
11.1% (4/36) suggests that sorafenib has no meaningful activity as
a single agent in metastatic melanoma patients (the primary
endpoint of the study was response rate). With respect to
previously described activity of sorafenib in melanoma, mono-
therapy lead to tumor growth inhibition, but not tumor shrinkage
in melanoma tumor xenografts [9,16]. Furthermore, no PR’s were
seen in 37 advanced melanoma patients who were treated with
sorafenib monotherapy as part of a randomized discontinuation
trial [17]. The toxicity profile was similar to that noted in other
clinical trials using sorafenib.
The importance of MAPK pathway upregulation and the high
prevalence of the BRAF
V600E mutation in melanoma patients in
conjunction with preclinical data showing that BRAF blockade
results in apoptosis and tumor control in preclinical models
provided the rationale for investigating sorafenib in this trial. The
most obvious explanation for the limited activity of sorafenib in
melanoma as a single agent is its lack of specificity and relatively
low effectiveness as a BRAF kinase inhibitor. New compounds
with higher selectivity and potency for mutant BRAF, PLX4720
[24] and PLX4032 [10], are in preclinical and clinical develop-
ment. PLX4032 has been studied as single agent in patients with
solid tumors (mainly melanoma patients) and responses, including
complete responses, were seen in the majority of patients whose
tumors were harboring the BRAF
V600E mutation [25]. If an
upregulated MAPK pathway is in fact the most important
mechanism that drives tumor proliferation in melanomas carrying
the BRAF
V600E mutation, the high selectivity and potency of these
new agents should provide more insight into the role of BRAF as a
critical therapeutic target in melanoma.
An explanation for the (albeit low) activity of sorafenib
independent of BRAF inhibition might be explained by the effect
of sorafenib on other targets, such as VEGFR2 (which has recently
beenassociated withresponseto sorafenibgivenincombination with
chemotherapy in metastatic melanoma patients [26]), or c-KIT.
Of note, there were 2 patients with an unconfirmed PR who had
a mucosal melanoma. One of these 2 patients (subject #19)
tested negative for c-kit mutations in exons 11, 13, 17, and 18, while
no information on the c-kit status of subject #14 is available.
Approximately 40% of patients with mucosal melanoma have c-kit
aberrations in exons 11, 13, and 17, and clinical responses, including
CR’s, were seen in these patients after treatment with imatinib
[27,28,29,30]. Notably, a recent case report documented a PR in a
patient with the D820Y mutation in exon 17 of KIT who was treated
with sorafenib [31]. Pharmacogenomic studies to elucidate the
Figure 2. Cyclin D1 and Ki67 expression in tumor biopsies obtained before and after treatment with sorafenib. A: Increase/decrease in
the percentage of tumor cells staining for cyclin D1 and Ki67 between pre-treatment (day 1) and post-treatment (day 28) samples, as measured by
immunohistochemistry. The numbers represent absolute changes in percentage of cells. B: Representative stainings for cyclin D1 and Ki67 from
patient #20 are shown (406).
doi:10.1371/journal.pone.0015588.g002
Table 2. Toxicity profile.
Toxicity grade
Grade 1 and 2 Grade 3
n% n %
Constitutional
Fatigue 5 13 1 3
Anorexia 3 8 0 0
Gastrointestinal
Mucositis 6 16 0 0
Diarrhea 11 30 0 0
Intestinal perforation 0 0 1 3
Nausea/Vomiting 6 16 0 0
Dermatological
Hand-Foot syndrome 6 16 2 5
Rash 17 46 2 5
Alopecia 8 22 0 0
Flushing 3 8 0 0
Dry skin 6 16 0 0
Neurological
Neuropathy 3 8 0 0
Pain 8 22 0 0
Miscellaneous
Dyspnea 0 0 1 3
Hypertension 2 5 0 0
doi:10.1371/journal.pone.0015588.t002
Table 3. Tumor responses and BRAF mutational status.
Response BRAF
V600E
by sequencing by MSPCR
wt mutant wt mutant
PR 01 01
SD 30 30
PD 22 3 8 16
doi:10.1371/journal.pone.0015588.t003
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underway as part of ongoing clinical trials in melanoma and other
tumor types.
Noteworthy is a recent report by Karreth et al., showing that
CRAF inhibits BRAF
V600E kinase activity and that sorafenib at
low doses, through its inhibitory effect on CRAF, can lead to
increased MAPK pathway activation [32]. These findings were
recently corroborated and expanded by 2 groups, reporting that
ATP competitive RAF inhibition, through transactivation of the
non-inhibited member of CRAF-CRAF homodimers or CRAF-
BRAF heterodimers, leads to increased signaling through the
RAF-MEK-ERK pathway in BRAF wild-type tumors, resulting in
increased tumor growth [33,34]. This evidence highlights the
importance of knowledge of the BRAF status in patients treated
with specific RAF inhibitors such as PLX4032. We speculate that
these new findings could explain some of our findings in the study,
such as upregulation of cyclin D1 and Ki67 after treatment with
sorafenib in 2 patients and the absence of a correlation between
BRAF status and clinical benefit in our patient population.
Sixty percent of patients had a melanoma carrying the
BRAF
V600E mutation as assessed by MSPCR, which is compara-
ble to the mutation rate previously seen in melanoma [4,35,36].
Table 4. Tumor characteristics and response to sorafenib for individual patients.
# Age Gender
BRAF
V600E
(sequ)
BRAF
V600E
(MSPCR) Primary site metastatic site
# of
sites AJCC StageLDH Response
1 79 F W M cutaneous ST, liver, bone, lymph node 4 IVM1c nl PD
2 91 M W W cutaneous skin, lymph node 2 IVM1a nl NE
3 69 M M M cutaneous ST, lung 2 IVM1b nl PR
4 71 M W M cutaneous lymph node 1 IVM1a nl PD
5 22 M W M cutaneous ST, liver, lung, kidney, spine 5 IVM1c h NE
6 67 F W M cutaneous ST, lung, liver, lymph node 4 IVM1c h PD
7 53 m W W ocular ST, lymph node, liver, lung 4 IVM1a nl PD
8 49 M W M cutaneous ST, lymph node 2 IVM1a nl PD
9 47 F M M cutaneous ST, lung, bone, adrenal,
lymph node
5 IVM1c h PD
10 84 M W W cutaneous ST, lymph node 2 IVM1c h PD
11 42 M W W cutaneous skin, lung 2 IVM1b h SD
12 62 M W W cutaneous ST, lung, liver, kidney, gall bladder 5 IVM1c h SD
13 59 F W W cutaneous ST, lymph node 2 IVM1a nl SD
14 59 F W W mucosal ST, lymph node 2 IVM1c h PD
15 61 F W W cutaneous skin 1 IVM1a nl PD
16 77 M W W cutaneous liver, lung, lymph node 3 IVM1c h PD
17 55 F M na unknown lung, lymph node 2 IVM1c h NE
18 79 M W M cutaneous ST, bone, lymph node 3 IVM1c h PD
19 68 M W W mucosal liver, lung, adrenal, lymph node 4 IVM1c h PD
20 42 F W M cutaneous lung, bone, skin, ST, lymph node 5 IVM1c nl PD
21 75 M W W cutaneous lymph node 1 IIIc h PD
22 68 M W M cutaneous liver, adrenal, ST, lymph node 4 IVM1c h PD
23 72 M W M cutaneous lung, adrenal, mediastinum, ST,
brain
5 IVM1c h PD
24 47 M na na cutaneous lung 1 IVM1b nl NE
25 65 F W W cutaneous soft tissue 1 IVM1a nl PD
26 83 M W M cutaneous soft tissue, lymph node 2 IVM1a nl PD
27 71 M W M cutaneous soft tissue 1 IVM1c h PD
28 71 F M M cutaneous lymph node, soft tissue, lung 3 IVM1c h PD
29 37 M W M cutaneous soft tissue, lung 2 IVM1b nl PD
30 34 F M na cutaneous lymph node, liver 2 IVM1a nl NE
31 75 M W na cutaneous lymph node, ST, spleen, kidney 4 IVM1c h PD
32 34 F M M cutaneous soft tissue, bone 2 IIIc nl PD
33 57 F na na cutaneous soft tissue, skin 2 IVM1a nl PD
34 53 F w M cutaneous soft tissue, lung 2 IVM1b nl PD
35 64 F na na cutaneous lymph node, lung 2 IVM1b nl PD
36 54 F W M mucosal vulva, cervix 2 IVM1a nl PD
MSPCR: mutant specific PCR; h:high; na: not available; AJCC: American Joint Committee on Cancer.
doi:10.1371/journal.pone.0015588.t004
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mutation by sequencing in our study could be contamination of
the soft tissue metastases (from which all biopsies were obtained)
with normal tissue. In a previous study, we showed that the
sensitivity of DNA sequencing is much lower compared to
MSPCR [22]. Of note, in that analysis soft tissue melanoma
metastases had a lower BRAF
V600E mutation rate compared to
lymph node and visceral metastases (32% vs. 45–50%). In our
opinion a highly sensitive technique such as MSPCR or TaqMan
Real Time PCR, using sequence specific probes (as is being used in
the ongoing PLX4032 phase 3 trial [37]) is desirable and the
preferred method over conventional DNA sequencing for BRAF
mutation testing.
Expression of cyclin D1 and Ki67 (all proteins located
downstream of the BRAF kinase) were analyzed by immunohis-
tochemistry in paired tumor biopsies (pre- and post treatment)
from 15 of 36 patients. Expression of the 2 markers was highly
variable, ranging from 0–90% of tumor cells. Similar variability in
expression levels of 10 other direct targets or downstream
mediators of sorafenib was seen in a study of melanoma patients
who were treated with sorafenib in addition to carboplatin and
paclitaxel [19,26]. When we compared pre- and post treatment
tumor samples, the expression of the 2 markers was lower in the
majority of post-treatment specimens (Fig. 2), however this did not
reach statistical significance. The biologic relevance (whether this
reflects a treatment effect) is not clear as the differences were low in
absolute numbers mainly because of the low baseline expression in
many of the tumors. It is important to emphasize that we did
perform quantitative analysis on 5 different, full tumor sections for
each tumor specimen, thus evaluating the staining of several
thousand tumor cells for each sample. We are therefore confident
that the numbers are accurate even in cases were low numbers of
tumor cells staining for the respective markers were seen. The data
suggest that sorafenib does not inhibit the MAPK pathway in the
advanced melanoma patients studied here. Due to the low RR in
this study we are unable to conclude whether tumor response was
associated with a more pronounced decrease of cyclin D1 and
Ki67 compared to non-responders.
It is well known that other pathways in addition to the MAPK
cascade, such as the PI3K/AKT pathway, play a role in
oncogenesis in melanoma, and inhibition of multiple pathways
was shown to be synergistic in melanoma cell lines [38]. A number
of these pathways are not affected by sorafenib and it has been
proposed that rational combination of specific targeted agents
depending on genetic subtypes of melanoma (for example
BRAF
V600E mutant melanoma with other genetic aberrations
such as PTEN deletion or AKT amplification) might be a
promising strategy to tailor treatment for optimal efficacy in
melanoma.
In conclusion, sorafenib at the evaluated dose of 400 mg twice
daily has limited activity in metastatic melanoma as a single agent.
BRAF
V600E mutational status was detected more frequently by
MSPCR compared to conventional PCR sequencing. We did not
find a significant impact on the MAPK pathway in the tumors as
measured by immunohistochemical analysis of cyclin D1 and Ki67
after treatment with sorafenib. No evidence for correlation
between BRAF
V600E mutational status of the tumor and clinical
activity was found, suggesting that sorafenib is not an effective
BRAF inhibitor or that additional sorafenib targets may play a role
in the few patients who benefit from the drug.
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